[go: up one dir, main page]

AR076555A1 - GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE - Google Patents

GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE

Info

Publication number
AR076555A1
AR076555A1 ARP100101582A ARP100101582A AR076555A1 AR 076555 A1 AR076555 A1 AR 076555A1 AR P100101582 A ARP100101582 A AR P100101582A AR P100101582 A ARP100101582 A AR P100101582A AR 076555 A1 AR076555 A1 AR 076555A1
Authority
AR
Argentina
Prior art keywords
antigen
vaccine
antibody
ldnf
gal
Prior art date
Application number
ARP100101582A
Other languages
Spanish (es)
Inventor
Irma Marianne Die
Boris Tefsen
Die Irma Marianne Van
Original Assignee
Stichting Tech Wetenschapp
Vereniging Voor Christelijk Hoger Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp, Vereniging Voor Christelijk Hoger Onderwijs filed Critical Stichting Tech Wetenschapp
Publication of AR076555A1 publication Critical patent/AR076555A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere al campo de la inmunología parasitaria veterinaria. En forma más específica, la solicitud se refiere a una estructura de carbohidratos util para el tratamiento inmunoprotector y para la prevencion o reduccion de las infecciones causadas por los nematodos parasíticos en los rumiantes. Particularmente, la solicitud se refiere a un antígeno que comprende la estructura de carbohidratos, a un anticuerpo específico para la estructura de carbohidratos, a una vacuna que comprende el antígeno o el anticuerpo, al uso del antígeno, el anticuerpo o la vacuna, y a los métodos de tratamiento y métodos de fabricacion. Reivindicacion 1: Un antígeno que comprende un carbohidrato correspondiente a la formula estructural Gala1-3GalNAcb1-4(Fuca1-3)GlcNAc (en lo sucesivo: Gal-LDNF). Reivindicacion 2: El antígeno de acuerdo con la reivindicacion 1, que comprende la Gal-LDNF en una estructura química de la formula: Gal-LDNF-R, caracterizado porque R denota una estructura inmunogénica, a la cual se adjunta la unidad de GlcNAc de la Gal-LDNF. Reivindicacion 3: El antígeno de acuerdo con la reivindicacion 2, caracterizado porque la estructura inmunogénica R se selecciona entre el grupo que consiste en carbohidratos, proteínas y lípidos. Reivindicacion 5: El antígeno de acuerdo con la reivindicacion 4, caracterizado porque R2 comprende, adicionalmente, una porcion de diaminopiridina que adjunta R2 a R1.The present application refers to the field of veterinary parasitic immunology. More specifically, the application refers to a carbohydrate structure useful for immunoprotective treatment and for the prevention or reduction of infections caused by parasitic nematodes in ruminants. Particularly, the application refers to an antigen comprising the carbohydrate structure, a specific antibody for the carbohydrate structure, a vaccine comprising the antigen or the antibody, the use of the antigen, the antibody or the vaccine, and treatment methods and manufacturing methods. Claim 1: An antigen comprising a carbohydrate corresponding to the structural formula Gala1-3GalNAcb1-4 (Fuca1-3) GlcNAc (hereinafter: Gal-LDNF). Claim 2: The antigen according to claim 1, comprising Gal-LDNF in a chemical structure of the formula: Gal-LDNF-R, characterized in that R denotes an immunogenic structure, to which the GlcNAc unit of the Gal-LDNF. Claim 3: The antigen according to claim 2, characterized in that the immunogenic structure R is selected from the group consisting of carbohydrates, proteins and lipids. Claim 5: The antigen according to claim 4, characterized in that R2 additionally comprises a portion of diaminopyridine that attaches R2 to R1.

ARP100101582A 2009-05-11 2010-05-10 GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE AR076555A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159945 2009-05-11
US17742209P 2009-05-12 2009-05-12

Publications (1)

Publication Number Publication Date
AR076555A1 true AR076555A1 (en) 2011-06-22

Family

ID=40941929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101582A AR076555A1 (en) 2009-05-11 2010-05-10 GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE

Country Status (3)

Country Link
AR (1) AR076555A1 (en)
UY (1) UY32621A (en)
WO (1) WO2010130683A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022027A1 (en) 2014-08-04 2016-02-11 Synaffix B.V. Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
ES2659816T3 (en) 2015-04-23 2018-03-19 Synaffix B.V. Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from one (1,4) -n-acetylgalactosaminyltransferase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS021402A0 (en) * 2002-01-30 2002-02-21 Agresearch Limited Novel monoclonal antibody and nematode larval antigens

Also Published As

Publication number Publication date
UY32621A (en) 2010-12-31
WO2010130683A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
MX2019012598A (en) METHOD FOR FORMULATION OF DRUG BASED ON INCREASING AFFINITY OF ACTIVE AGENTS TOWARDS THE SURFACES OF CRYSTALLINE MICROPARTICLES.
CL2014003509A1 (en) Soft chewable veterinary composition comprising as active agent an isoxazoline derivative compound; and its use for the treatment and / or prevention of an infestation and / or infection by parasites in an animal (div. sol. n ° 2087-14).
DOP2013000092A (en) SOLID DISPERSIONS EXTRUDED BY FUSION CONTAINING AN ADOPTOSIS INDUCTIVE AGENT
IT1394401B1 (en) SYSTEM AND PROCEDURE TO FACILITATE THE TREATMENT AND PRODUCTION IN A FORCE OF WELL.
PE20150200A1 (en) FORMULATION OF ANTIBODIES
DOP2012000312A (en) SUBSTITUTED TRIAZOLOPIRIDINS
SV2011003888A (en) COMPOUNDS THAT EXPAND HEMATOPOIETIC MOTHER CELLS
AR081558A1 (en) EXTRACTION OF CELL LIPIDS AND PRODUCTS FROM THEM
CL2012002195A1 (en) Immunogenic composition comprising a mixture of polysaccharide-multivalent protein conjugates consisting of capsular polysaccharides of streptococcus pneumoniae; method to induce an immune response to a capsular polysaccharide of streptococcus pneumoniae.
AR082630A1 (en) ANTI-TENASCINE-C A2 ANTIBODIES AND METHODS OF USE
IT1403661B1 (en) EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
PA8840801A1 (en) DIOXA-BICYCLE DERIVAOS [3.2.1] OCTANO-2,3,4-TRIOL
MX2015015152A (en) FORMULATIONS OF BIESPECIFIC ANTIBODIES ANTI-IL-4 / ANTI-IL-13.
BR112013023876A2 (en) pyrroltriazinone derivatives as pi3k inhibitors
AR082686A1 (en) VACCINE ASSISTANTS DIRECTING ANTIBODY ADJUSTERS DIRECTLY TOWARDS ANTIGEN PRESENTING CELLS
ES2626850T3 (en) Flocculation treatment agent
PE20190458A1 (en) NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS OF THE SAME
CL2011003113A1 (en) Aqueous adjuvant composition comprising a tlr-4 agonist and a saponin and a non-ionic isotonicity agent; process for the preparation of an immunogenic composition.
CL2011003281A1 (en) Composition and procedures for disinfecting, destroying or inhibiting a pathogenic microorganism consisting of applying the composition comprising 2-ethylexyl sulfate or a salt thereof, an alkylbenzenesulfonic acid, naoh or koh, and a carrier; procedures using said composition to clean surfaces.
BR112015019278A2 (en) multi-impulse elastography process
CL2013001935A1 (en) Aqueous acid formulation comprising a first fluorocarbon linked peptide; method to obtain said formulation; use of said formulation to treat or prevent pathogenic infection, an autoimmune disease or cancer.
EA201500701A1 (en) METHOD OF CREATING A VACCINE AGAINST MYCOPLASM
CR10143A (en) ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME AND METHODS OF USE IN CANCER THERAPY
ECSP11011518A (en) PROCEDURE TO PRODUCE DERIVATIVES OF PYRIPYROPEN
CL2012003105A1 (en) Genetically designed commensal bacterium of the female genital tract that expresses an anti sperm agent; composition comprising said bacterium; use of said composition for the reduction of the incidence of pregnancy in a female population; intravaginal insertion device.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal